resectable stage III(N2) NSCLC
SAKK
II
Neo-adjuvant
Immune-modulatory radiotherapy to enhance the effects of neoadjuvant Durvalumab
HUG
To evaluate whether the addition of immune-modulatory radiotherapy to standard neoadjuvant chemotherapy with cisplatin/docetaxel and peri-operative immunotherapy with the anti-PD-L1 antibody durvalumab in primarily resectable stage III(N2) NSCLC is efficacious and feasible.